RPL17 and hepatocellular carcinoma: Herein, we conducted the current study to investigate the efficacy and of HAIC combined with lenvatinib and PD-1 immunotherapy in the first-line treatment of patients with advanced hepatocellular carcinoma with macrovascular invasion.